Primary completion· ClinicalTrials.gov
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
REGN13335 History and Updates
7 events · 2023 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
0
FDA Approvals
0
Label Revisions
7
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-01Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for REGN13335 since 2023, drawn from openFDA, ClinicalTrials.gov, and PubMed.
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Past events
2026
Trial started· ClinicalTrials.gov
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Trial registered· ClinicalTrials.gov
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
2025
Primary completion· ClinicalTrials.gov
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Health
2023
Trial started· ClinicalTrials.gov
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Health
Trial registered· ClinicalTrials.gov
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Health
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.